Mandate

Vinge has advised Consolid on the establishment of Consolid Equity III

July 02, 2025 Private Funds

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.

Consolid invests in high-potential business services companies, providing the expertise, ideas, and capital they need to grow and scale. By partnering closely with entrepreneurs, Consolid creates opportunities to innovate, tackle challenges, and build businesses that redefine their industries.

 

Vinge's team primarily consisted of Mattias Schömer, Marcus Andersson, Ulf Nilsson, Emelie Svanberg, Anton Sjökvist, Semir Omerbasic, Rebecka Margolin, Tobias Onegård Karlsson, Marcus Svärd, Saga Meyer Viklund, Emelie Zingmark and Lovisa Lagerkvist.

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026